Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Analysis of CYP17, CYP19 and CYP1A1 Gene Polymorphisms in Iranian Women with Breast Cancer

  • Farzaneh, Farah (Infertility and Reproductive Health Research Centre (IRHRC), Shahid Beheshti University of Medical Sciences) ;
  • Noghabaei, Giti (Preventive Gynecology Research Centre (PGRC), Shahid Beheshti University of Medical Sciences) ;
  • Barouti, Esmat (Infertility and Reproductive Health Research Centre (IRHRC), Shahid Beheshti University of Medical Sciences) ;
  • Pouresmaili, Farkhondeh (Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences) ;
  • Jamshidi, Javad (Noncommunicable Diseases Research Center, Fasa University of Medical Sciences) ;
  • Fazeli, Atena (Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences) ;
  • Taghavi, Shaghayegh (Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences) ;
  • Emamalizadeh, Babak (Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences) ;
  • Darvish, Hossein (Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences)
  • Published : 2016.06.01
Download PDF
⟨ Previous Next ⟩

Abstract

Breast cancer (BC) is the most common cancer and the second cause of mortality in women all around the world. It is caused by several factors including genetic determinants, so that both genetic susceptibility factors and environmental factors are involved in the etiology. Significance of genes functioning in steroid hormone synthesis and metabolism are well established in breast cancer susceptibility. In this study, 134 women with BC and 135 normal controls were analyzed for their genotypes for the polymorphisms, rs743572, rs10046 and rs4646903, resided in CYP17, CYP19 and CYP1A1 genes, respectively. Significant differences in distributions of allele and genotype frequencies were found for the rs10046 polymorphism in CYP19 (p-value=0.01, OR (CI 95%) =1.59 (1.1-2.3), p-value=0.04, OR (CI 95%) =1.7 (1.1-2.5) respectively). For rs743,572 and rs 4646903 polymorphisms, no significant associations were observed. A significant association was observed between the rs10046 polymorphism of the CYP19gene and breast cancer in Iranian patients. Due to inconsistent previous results, more studies in different populations with larger sample sizes are indicated.

Keywords

References

  1. Artamonov VV, Liubchenko LN, Shabanov MA, et al (2003). [Association of polymorphism of genetic markers of CYP19 and CYP17 with sporadic breast cancer]. Mol Biol (Mosk), 37, 975-82.
  2. Bampali K, Grassos C, Mouzarou A, et al (2015). Genetic variant in the CYP19A1 gene associated with coronary artery disease. Genet Res Int, 25, 820323.
  3. Bugano DD, Conforti-Froes N, Yamaguchi NH, et al (2008). Genetic polymorphisms, the metabolism of estrogens and breast cancer: a review. Eur J Gynaecol Oncol, 29, 313-20.
  4. Chen X, Truong TT, Weaver J, et al (2006). Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression. Hum Mutat, 27, 427-35. https://doi.org/10.1002/humu.20319
  5. Cribb AE, Joy Knight M, Guernsey J, et al (2011). CYP17, catechol-o-methyltransferase, and glutathione transferase M1 genetic polymorphisms, lifestyle factors, and breast cancer risk in women on Prince Edward Island. Breast J, 17, 24-31. https://doi.org/10.1111/j.1524-4741.2010.01025.x
  6. Duan J, Wainwright MS, Comeron JM, et al (2003). Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet, 12, 205-16. https://doi.org/10.1093/hmg/ddg055
  7. Eccles DM, Pichert G (2005). Familial non-BRCA1//BRCA2-associated breast cancer. Lancet Oncol, 6, 705-11. https://doi.org/10.1016/S1470-2045(05)70318-1
  8. Enger SM, Ross RK, Henderson B, et al (1997). Breastfeeding history, pregnancy experience and risk of breast cancer. Br J Cancer, 76, 118-23. https://doi.org/10.1038/bjc.1997.346
  9. Fry-Johnson YW, Rowley DL (2010). The enigma of spontaneous preterm birth. N Engl J Med, 362, 2032-4. https://doi.org/10.1056/NEJMc1002978
  10. Gonzalez JR, Armengol L, Sole X, et al (2007). SNPassoc: an R package to perform whole genome association studies. Bioinformatics, 23, 644-5.
  11. Haiman CA, Hankinson SE, Spiegelman D, et al (2002). No association between a single nucleotide polymorphism in CYP19 and breast cancer risk. Cancer. Epidemiol Biomarkers Prev,11, 215-6.
  12. Han DF, Zhou X, Hu MB, et al (2005). Polymorphisms of estrogen-metabolizing genes and breast cancer risk: a multigenic study. Chin Med J (Engl), 118, 1507-16.
  13. Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49. https://doi.org/10.3322/caac.20006
  14. Jin Y, Dietz HC, Montgomery RA, et al (1996). Glanzmann thrombasthenia. Cooperation between sequence variants in cis during splice site selection. J Clin Invest, 98, 1745-54. https://doi.org/10.1172/JCI118973
  15. Kiruthiga PV, Kannan MR, Saraswathi C, et al (2011). CYP1A1 gene polymorphisms: lack of association with breast cancer susceptibility in the southern region (Madurai) of India. Asian Pac J Cancer Prev, 12, 2133-8.
  16. McCullough LE, Santella RM, Cleveland RJ, et al (2014). Polymorphisms in DNA repair genes, recreational physical activity and breast cancer risk. Int J Cancer, 134, 654-63. https://doi.org/10.1002/ijc.28383
  17. Naghavi M, Abolhassani F, Pourmalek F, et al (2009). The burden of disease and injury in Iran 2003. Popul Health Metr, 7, 9-14. https://doi.org/10.1186/1478-7954-7-9
  18. Sattin RW, Rubin G, Wingo PA, et al (1986). Oral-contraceptive use and the risk of breast cancer. The cancer and steroid hormone study of the centers for disease control and the national institute of child health and human development. N Engl J Med, 315, 405-11. https://doi.org/10.1056/NEJM198608143150701
  19. Shen Y, Li DK, Wu J, et al (2006). Joint effects of the CYP1A1 MspI, ERalpha PvuII, and ERalpha XbaI polymorphisms on the risk of breast cancer: results from a population-based case-control study in Shanghai, China. Cancer Epidemiol Biomarkers Prev, 15, 342-7. https://doi.org/10.1158/1055-9965.EPI-05-0485
  20. Shimada T, Fujii-Kuriyama Y (2004). Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1. Cancer Sci, 95, 1-6. https://doi.org/10.1111/j.1349-7006.2004.tb03162.x
  21. Shin A, Kang D, Choi JY, et al (2007). Cytochrome P450 1A1 (CYP1A1) polymorphisms and breast cancer risk in Korean women. Exp Mol Med, 39, 361-6. https://doi.org/10.1038/emm.2007.40
  22. Taioli E, Trachman J, Chen X, et al (1995). A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women. Cancer Res, 55, 3757-8.
  23. Wu MH, Chou YC, Yu JC, et al (2006). Hormonal and body-size factors in relation to breast cancer risk: a prospective study of 11,889 women in a low-incidence area. Ann Epidemiol, 16, 223-9.
  24. Yang L, Wang XY, Li YT, et al (2015). CYP19 gene polymorphisms and the susceptibility to breast cancer in Xinjiang Uigur women. Genet Mol Res, 14, 8473-82. https://doi.org/10.4238/2015.July.28.15
  25. Zhang L, Gu L, Qian B, et al (2009). Association of genetic polymorphisms of ER-alpha and the estradiol-synthesizing enzyme genes CYP17 and CYP19 with breast cancer risk in Chinese women. Breast Cancer Res Treat, 114, 327-38. https://doi.org/10.1007/s10549-008-9998-0
  26. Zins K, Mogg M, Schneeberger C, et al (2014). Analysis of the rs10046 polymorphism of aromatase (CYP19) in premenopausal onset of human breast cancer. Int J Mol Sci, 15, 712-24. https://doi.org/10.3390/ijms15010712